<DOC>
	<DOCNO>NCT00916058</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Bendamustine ( TREANDA™ ) , combination Melphalan subject multiple myeloma undergo Autologous Stem Cell Transplant .</brief_summary>
	<brief_title>Conditioning Regimen Bendamustine Melphalan Followed Transplant Patients With Multiple Myeloma</brief_title>
	<detailed_description>Bendamustine ( TREANDA™ ) use clinical trial treat multiple myeloma . The result trial suggest may beneficial treatment multiple myeloma different treatment context . Researchers aim determine may improve benefit context bone marrow transplant . This initial clinical trial intend help determine safe use bendamustine condition regimen bone marrow transplant , look initial evidence benefit . Bendamustine ( TREANDA™ ) approve Food Drug Administration ( FDA ) treatment Chronic Lymphocytic Leukemia Melphalan type chemotherapy drug . The use Melphalan alone condition regimen Autologous Stem Cell Transplant consider `` Standard Care , '' , treatment process doctor would normally follow treat disease . Although Bendamustine ( TREANDA™ ) use multiple myeloma research study , combination Bendamustine ( TREANDA™ ) Melphalan treatment Multiple Myeloma approve FDA , thus combination therapy use research study consider `` investigational . ''</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients multiple myeloma receive induction therapy stem cell mobilize preparation autologous transplantation eligible study . Patients also eligible relapsed refractory disease , attempt standard approach , availability stem cell . Patients must age 18 old . Patients must life expectancy least 12 week . Patients must ECOG performance status 0 , 1 2 . Patients must provide write informed consent . Impaired renal function measure calculated creatinine clearance le 25 ml/min . Impaired hepatic function define bilirubin great 1.5 x upper limit normal ( ULN ) ALT AST great 5 x ULN . Serious active uncontrolled infection medical condition . Women pregnant breast feeding . Women childbearing age must use adequate contraception negative pregnancy test . Impaired pulmonary function DLCO le 45 % predict . Impaired cardiac function ejection fraction le 40 % predict . Other systemic anticancer therapy ongoing toxicity therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>ASCT</keyword>
	<keyword>MM</keyword>
</DOC>